MXCT News and Press, MaxCyte Inc. From 05/09/22

GAITHERSBURG, Md., May 09, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, de...

Gainers: Evelo Biosciences, Inc. (EVLO) +5%. CymaBay Therapeutics Inc. (CBAY) +5%. Allakos Inc. (ALLK) +5%. Diversified Healthcare Trust (DHC) +4%. Angi Inc. (ANGI) +3%. Losers: Dogness (International) Corporation (DOGZ) -5%. MaxCyte, Inc. (MXCT) -4%. FTC Solar, Inc. (FTCI...

GAITHERSBURG, Md., April 20, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, ...

MaxCyte (NASDAQ:MXCT) said on Tuesday that Amanda Murphy has resigned as its chief financial officer, effective Apr. 15, to pursue other interests. The healthcare cell-engineering company told its current SVP and chief accounting officer Ron Holtz has been named as its interim CFO u...

GAITHERSBURG, Md., April 12, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, ...

BAMCO’s 13F portfolio value increased from $44.15B to $47.14B this quarter. Ron Baron increased Taiwan Semi, Iridium Communications, and Spotify while dropping Zillow Group. Their top five positions are at ~27% of the overall portfolio. For further details see: Tr...

Image source: The Motley Fool. MaxCyte, Inc. (NASDAQ: MXCT) Q4 2021 Earnings Call Mar 22, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: MaxCyte, Inc. (MXCT) Q4 2021 Earnings Call Transcript

MaxCyte, Inc. (MXCT) Q4 2021 Earnings Conference Call March 22, 2022 4:30 PM ET Company Participants Sean Menarguez - Investor Relations Doug Doerfler - President and Chief Executive Officer Amanda Murphy - Chief Financial Officer Conference Call Participants Jacob Johnson - Stephens Inc. Jul...

MaxCyte press release (NASDAQ:MXCT): Q4 GAAP EPS of -$0.05 beats by $0.01. Revenue of $10.2M (+18.6% Y/Y) beats by $0.49M. For further details see: MaxCyte GAAP EPS of -$0.05 beats by $0.01, revenue of $10.2M beats by $0.49M

GAITHERSBURG, Md., March 22, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT) is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery...